Bronchopulmonary Dysplasia (BPD)

1. Topic Overview (Clinical Overview)

Summary

Bronchopulmonary Dysplasia (BPD), also known as Chronic Lung Disease of Prematurity (CLD), is the most common serious respiratory complication affecting preterm infants, particularly those born at extremely low gestational ages (less than 28 weeks) or with extremely low birth weights (less than 1000g). [1,2] The condition represents a complex developmental disorder characterised by disrupted alveolar and pulmonary vascular development resulting from the premature lung's maladaptive response to postnatal injury.

The pathogenesis involves a multifactorial interplay of mechanical ventilation-induced injury (volutrauma/barotrauma), oxygen toxicity and oxidative stress, prenatal and postnatal inflammation, and impaired signalling pathways essential for alveolarisation. [3] The National Institute of Child Health and Human Development (NICHD) defines BPD as the requirement for supplemental oxygen for at least 28 cumulative days, with severity assessment performed at 36 weeks postmenstrual age (PMA). [1]

The introduction of surfactant therapy in the 1990s transformed the phenotype of BPD from the "old BPD" described by Northway in 1967—characterised by severe fibrosis and airway remodelling—to "new BPD," which primarily manifests as arrested alveolar development with simplified, enlarged alveoli and abnormal pulmonary vasculature. [4,5] Despite advances in neonatal care, BPD continues to affect 25-50% of extremely low birth weight infants and remains a leading cause of long-term respiratory morbidity. [2]

Evidence-based prevention strategies including antenatal corticosteroids, early caffeine citrate administration, surfactant replacement, non-invasive respiratory support, and judicious oxygen targeting have reduced severe BPD incidence, though the overall burden remains substantial. [6,7,8] Long-term management encompasses optimised respiratory support, prevention of respiratory infections (particularly RSV via Palivizumab prophylaxis), nutritional optimisation, and systematic surveillance for pulmonary hypertension and neurodevelopmental outcomes. [9,10]

Key Facts

Domain	Critical Information
Definition (NICHD 2001)	Supplemental oxygen requirement for ≥28 days; severity graded at 36 weeks PMA [1]
Incidence	40-70% in ELBW (less than 1000g); 25-50% in less than 28 weeks gestation [2]
Primary Pathophysiology	Arrested alveolar development with simplified, larger alveoli; dysmorphic pulmonary vasculature [5]
Key Risk Factors	Extreme prematurity, low birth weight, mechanical ventilation, oxygen toxicity, chorioamnionitis, sepsis, PDA [3]
Prevention Cornerstones	Antenatal steroids (NNT ~10), Caffeine (CAP Trial), Surfactant, Early CPAP, SpO2 91-95% [6,7,8]
Treatment Principles	Optimised respiratory support, Nutrition (120-150 kcal/kg/day), Diuretics, Selective postnatal steroids
Critical Complication	Pulmonary hypertension (10-25% of severe BPD); significantly increases mortality [9]
Long-term Outcome	50-70% have abnormal spirometry in adulthood; risk of COPD-like phenotype [10]

Clinical Pearls

Clinical Pearl: "Old BPD vs New BPD": The classic Northway description (1967) of severe fibrotic lung disease in larger preterm infants is rarely seen today. "New BPD" in the post-surfactant era is primarily a developmental disorder—arrest of alveolarisation and vascular development in extremely preterm infants, with less fibrosis but potentially more challenging long-term outcomes. [4,5]

Clinical Pearl: "36 Weeks PMA: The Defining Moment": BPD severity is assessed at 36 weeks corrected gestational age. This single timepoint determines prognosis and guides discharge planning. Mild BPD (room air) has fundamentally different outcomes from severe BPD (≥30% FiO2 or positive pressure). [1]

Clinical Pearl: "Caffeine Citrate: The Wonder Drug": The CAP Trial demonstrated that caffeine reduces BPD/death (NNT 10), improves neurodevelopmental outcomes at 18 months, and has benefits persisting to 11 years. Start within 24 hours of birth in infants less than 30 weeks. [7,11]

Clinical Pearl: "RSV is the Silent Assassin": Infants with BPD have 5-10 times higher risk of severe RSV bronchiolitis requiring ICU admission. Palivizumab prophylaxis during RSV season is not optional—it is essential. [12]

Clinical Pearl: "The Oxygen Paradox": Oxygen saves lives but causes lung injury. The NeOProM meta-analysis demonstrated that targeting SpO2 85-89% reduces BPD but increases mortality by ~1%. Current consensus: target 91-95% to balance lung protection against survival. [8]

Why This Matters Clinically

BPD is the most prevalent chronic lung disease originating in infancy. With improving survival of extremely preterm infants (now > 80% survival at 24 weeks in developed nations), the absolute number of BPD survivors is increasing. Understanding evidence-based prevention—particularly the roles of antenatal steroids, caffeine, gentle ventilation strategies, and appropriate oxygen targeting—can substantially reduce disease burden. The long-term implications extend well beyond the NICU: BPD survivors are at increased risk for chronic respiratory symptoms, reduced exercise capacity, neurodevelopmental impairment, and a trajectory toward COPD-like disease in adulthood.

2. Epidemiology

Global Incidence and Prevalence

Population	BPD Incidence	Notes
less than 28 weeks gestation	40-80%	Highest risk group; inversely related to gestational age [2]
28-31 weeks gestation	10-25%	Moderate risk
32-34 weeks gestation	less than 5%	Low risk; usually only with significant comorbidities
ELBW (less than 1000g)	40-70%	Birth weight strongly predictive [2]
VLBW (1000-1500g)	15-30%	Lower but significant incidence

Temporal Trends

The epidemiology of BPD has evolved significantly over the past 50 years. [2,5]

Era	Characteristics
Pre-Surfactant (Before 1990)	"Old BPD" predominant; affected larger preterm (30-34 weeks); high mortality; severe fibrosis
Post-Surfactant (1990-2010)	"New BPD" emerges; affects smaller infants; improved survival of ELBW infants increases absolute numbers
Modern Era (2010-Present)	Despite improved prevention, BPD rates remain stable; survival of 23-24 weekers increases denominator

Geographic Variation

Significant variation exists between centres and countries, reflecting differences in practice patterns, patient populations, and definitions. [2] The Vermont Oxford Network reports BPD rates of 20-50% across member NICUs for infants less than 29 weeks, with substantial inter-centre variability not fully explained by patient characteristics.

Risk Factor Analysis

Major Risk Factors

Risk Factor	Relative Risk/Odds Ratio	Mechanism	Evidence Level
Gestational Age less than 26 weeks	OR 8-15	Lung developmental immaturity	High [2]
Birth Weight less than 750g	OR 5-10	Correlates with lung maturity	High [2]
Male Sex	OR 1.5-2.0	Delayed surfactant maturation; hormonal effects	High [2]
Mechanical Ventilation	OR 3-5	Volutrauma, barotrauma, atelectrauma	High [3]
Oxygen Exposure (FiO2 > 40%)	OR 2-4	Oxidative stress; free radical injury	High [8]
Chorioamnionitis	OR 1.5-2.5	Prenatal inflammation; altered lung development	High [3]
Postnatal Sepsis	OR 2-3	Systemic inflammation; cytokine storm	High [3]
Patent Ductus Arteriosus	OR 1.5-2.0	Pulmonary oedema; volume overload	Moderate [3]
White Ethnicity	OR 1.3-1.5	Genetic factors; controversial	Moderate [2]
Postnatal Growth Failure	OR 2-3	Impaired lung growth without adequate nutrition	High [13]

Protective Factors

Protective Factor	Effect Size	Mechanism
Antenatal Corticosteroids	NNT ~10 for BPD	Accelerate surfactant production; lung maturation [6]
Female Sex	OR 0.5-0.7	Earlier surfactant maturation; oestrogen effects
Appropriate for Gestational Age	OR 0.6-0.8	Better baseline lung development
Early Caffeine (less than 72 hours)	OR 0.6-0.7	Reduces ventilation duration; anti-inflammatory [7]
Non-invasive Respiratory Support	OR 0.7-0.8	Avoids ventilator-induced lung injury [14]

Survival and Mortality Context

Gestational Age	Survival (Developed Countries)	BPD Among Survivors
22 weeks	20-40%	80-90%
23 weeks	40-60%	70-80%
24 weeks	60-80%	50-70%
25 weeks	75-85%	40-60%
26 weeks	85-90%	30-50%
28 weeks	> 95%	15-30%

3. Pathophysiology

Fetal Lung Development: The Foundation

Understanding BPD requires appreciation of normal lung development. The premature lung is born during critical developmental windows. [5]

Stage	Gestational Age	Key Developmental Events	Clinical Relevance
Embryonic	3-7 weeks	Lung bud formation; Bronchial tree branching begins	Rarely relevant to BPD
Pseudoglandular	7-16 weeks	Complete airway branching; Cilia development	All airways formed by 16 weeks
Canalicular	16-26 weeks	Primitive alveolar ducts; Type I/II pneumocyte differentiation; Surfactant production begins	Most ELBW infants born here
Saccular	24-38 weeks	Terminal saccules form; Thinning of air-blood barrier; Capillary approximation	Zone of viability; Active gas exchange possible
Alveolar	36 weeks - 2-3 years	Secondary septation; True alveoli form; 20 million → 300 million alveoli	Continues postnatally; BPD disrupts this

Exam Detail: Critical Teaching Point: At 24 weeks gestation, the lung is in late canalicular/early saccular phase with approximately 20 million primitive air sacs. By term, this increases to 50-100 million, and by age 2-3 years, the adult complement of 300 million alveoli is achieved. BPD fundamentally arrests this alveolarisation process, resulting in "simplified" lungs with fewer, larger alveoli and reduced gas exchange surface area. [5]

"Old BPD" vs "New BPD": A Paradigm Shift

The phenotype of BPD has fundamentally changed since the introduction of surfactant therapy and gentler ventilation strategies. [4,5]

Feature	Old BPD (Northway 1967)	New BPD (Post-Surfactant Era)
Population	Larger preterm (30-34 weeks); Higher birth weights	Extremely preterm (less than 28 weeks); ELBW
Primary Injury	Severe ventilator trauma; High pressures/volumes; Prolonged high FiO2	Developmental arrest; Inflammation; Subtle injury accumulation
Histopathology	Fibrosis; Airway smooth muscle hypertrophy; Bronchial stenosis; Emphysematous cysts	Simplified alveoli; Fewer, larger alveoli; Dysmorphic pulmonary vasculature; Minimal fibrosis
Chest X-ray	Cystic changes; Fibrotic stranding; Marked hyperinflation	Hazy opacities; Mild hyperinflation; "Ground glass" areas
Outcome	High early mortality; Severe survivors	Improved survival; Subtle long-term impairment

Molecular Pathophysiology

Key Signalling Pathways Disrupted in BPD

Pathway	Normal Function	Disruption in BPD	Therapeutic Implications
VEGF/VEGFR	Vascular development; Alveolar septation	Decreased VEGF; Reduced angiogenesis; Impaired alveolarisation	Potential target; Animal studies promising [5]
TGF-β	Tissue remodelling; Fibrosis regulation	Elevated TGF-β; Excessive fibrosis; Impaired epithelial repair	Anti-TGF-β strategies experimental
Wnt/β-catenin	Lung morphogenesis; Stem cell maintenance	Dysregulated; Abnormal airway development	Research target
Notch Signalling	Cell fate determination; Alveolar differentiation	Altered expression; Type II pneumocyte dysfunction	Experimental
NF-κB	Inflammatory response	Persistently activated; Chronic inflammation	Steroids modulate
HIF-1α/2α	Hypoxia response; Vascular development	Dysregulated by hyperoxia/hypoxia cycling	Oxygen targeting critical

Cellular Mechanisms

Mechanism	Pathological Process	Consequence
Type II Pneumocyte Injury	Oxidative damage; Inflammatory insult	Reduced surfactant; Impaired alveolar repair
Endothelial Dysfunction	VEGF deficiency; Oxidative stress	Vascular simplification; Pulmonary hypertension
Fibroblast Activation	TGF-β excess; Myofibroblast differentiation	Interstitial thickening; Reduced compliance
Inflammatory Cell Infiltration	Neutrophil/Macrophage accumulation	Cytokine release; Protease damage
Extracellular Matrix Dysregulation	Abnormal elastin/collagen deposition	Reduced alveolar septation; Stiff lungs

The Four Pillars of BPD Pathogenesis

1. Mechanical Ventilation Injury

Type	Mechanism	Prevention Strategy
Volutrauma	Overdistension of alveoli → Epithelial stretch injury → Inflammatory cascade	Volume-targeted ventilation; Low tidal volumes (4-6 mL/kg) [14]
Barotrauma	High inspiratory pressures → Alveolar rupture → Air leak	Pressure limitation; Permissive hypercapnia
Atelectrauma	Repetitive opening/collapse of alveoli → Shear stress injury	Adequate PEEP; Open lung strategy
Biotrauma	Mechanical stress triggers inflammatory mediators	Minimise ventilation duration; Early CPAP [14]

Exam Detail: Volutrauma vs Barotrauma Debate: Contemporary evidence emphasises that volume (tidal volume) is more injurious than pressure per se. The COIN trial and SUPPORT trial demonstrated that avoiding intubation when possible (using CPAP) reduces BPD, supporting the concept that even "gentle" mechanical ventilation causes injury compared to non-invasive support. [14]

2. Oxygen Toxicity and Oxidative Stress

Mechanism	Cellular Effect	Clinical Manifestation
Free Radical Generation	Superoxide, Hydrogen peroxide, Hydroxyl radicals	Lipid peroxidation; DNA damage
Antioxidant Deficiency	Preterm infants lack mature SOD, Catalase, Glutathione systems	Inability to neutralise ROS
Mitochondrial Dysfunction	Electron transport chain damage	Cellular energy failure; Apoptosis
VEGF Suppression	Hyperoxia directly inhibits VEGF	Impaired vascular and alveolar development

The NeOProM meta-analysis (combining SUPPORT, BOOST II, and COT trials) demonstrated that targeting SpO2 85-89% reduced BPD compared to 91-95%, but increased mortality by approximately 1%. [8] This fundamental trade-off—the oxygen paradox—underlies current consensus to target 91-95%.

3. Inflammation (Prenatal and Postnatal)

Source	Mechanism	Evidence
Chorioamnionitis	Fetal inflammatory response syndrome (FIRS); Cytokine exposure in utero	Elevated IL-6, IL-8, TNF-α in amniotic fluid associated with BPD [3]
Postnatal Sepsis	Systemic inflammation; Pulmonary neutrophil infiltration	Each sepsis episode increases BPD risk by 20-30% [3]
Ventilator-Associated Inflammation	Mechanical stretch activates NF-κB; Cytokine release	Biotrauma component
Chronic Inflammation	Persistent macrophage activation in BPD lungs	Drives ongoing injury; Target for therapy

4. Nutritional Deficiency and Growth Failure

Deficiency	Effect on Lung	Prevention/Treatment
Caloric Deficit	Reduced lung growth; Impaired repair	120-150 kcal/kg/day target [13]
Protein Insufficiency	Decreased surfactant synthesis; Muscle wasting	3.5-4.5 g/kg/day protein
Vitamin A Deficiency	Impaired epithelial differentiation and repair	Vitamin A supplementation reduces BPD (NNT 13) [15]
Vitamin D Deficiency	Reduced lung maturation; Immune dysfunction	Supplementation; Target 50-80 nmol/L
LCPUFA Deficiency	Altered surfactant composition; Impaired anti-inflammatory responses	DHA/ARA supplementation under study

Pulmonary Vascular Pathology in BPD

The pulmonary vasculature is critically affected in BPD, with implications for pulmonary hypertension development. [9]

Vascular Change	Mechanism	Clinical Consequence
Reduced Vessel Number	VEGF deficiency; Impaired angiogenesis	Decreased vascular bed capacity
Vessel Muscularisation	Smooth muscle hyperplasia in small arteries	Increased pulmonary vascular resistance
Impaired Vasoreactivity	Endothelial dysfunction; Reduced NO signalling	Exaggerated hypoxic vasoconstriction
Vascular Pruning	Loss of peripheral vessels	Fixed pulmonary hypertension

4. Clinical Presentation

Acute Phase (NICU - First Weeks)

Clinical Feature	Description	Differential Considerations
Respiratory Distress	Tachypnoea (> 60/min), subcostal/intercostal retractions, nasal flaring, grunting	Initially indistinguishable from RDS
Oxygen Requirement	Persistent need for supplemental O2 beyond first 1-2 weeks	RDS typically improves by day 3-7
Ventilator Dependence	Difficulty weaning from mechanical ventilation or CPAP	Key feature differentiating from uncomplicated RDS
Recurrent Desaturations	Episodic oxygen desaturations, especially with handling or feeding	Reflects poor respiratory reserve
Apnoea/Bradycardia	May worsen as BPD evolves; often requiring caffeine continuation	Multifactorial aetiology
Poor Weight Gain	Increased caloric expenditure from respiratory effort	Need for fortified feeds

Transition Phase (Approaching Term Equivalent)

Feature	Clinical Significance
Persistent Oxygen Requirement at 36 Weeks PMA	Defines BPD and its severity
Chest Wall Deformity	Harrison's sulcus; Pectus excavatum (chronic respiratory effort)
Tachypnoea at Rest	Compensatory mechanism for reduced gas exchange surface
Feeding Intolerance	Coordination difficulties; High metabolic demand
Growth Velocity Plateau	Insufficient caloric intake relative to expenditure

Chronic Phase (Post-Discharge - First Years)

Feature	Prevalence	Management Implications
Home Oxygen Dependency	30-50% of severe BPD	Requires home oxygen service; oximetry monitoring
Recurrent Respiratory Infections	Very common	Low threshold for hospital assessment; RSV prophylaxis
Wheezing/Bronchospasm	30-40%	Often misdiagnosed as "asthma"; may be steroid-resistant
Exercise Intolerance	Emerges in toddlerhood	Reduced aerobic capacity
Feeding Difficulties	Oral aversion; GORD common	May require NG/gastrostomy feeding
Pulmonary Hypertension	10-25% of severe BPD	Requires Echo surveillance; specialist management [9]

Physical Examination Findings

System	Findings	Significance
Inspection	Tachypnoea; Increased WOB; Chest wall deformity	Chronic respiratory compromise
Palpation	Hyperinflation (barrel chest); Hepatomegaly (if cor pulmonale)	Severe disease; RV failure
Percussion	Hyperresonance	Air trapping
Auscultation	Crackles (especially bases); Wheeze; Reduced air entry	Variable; reflects severity
Cardiovascular	Loud P2; RV heave; Tricuspid regurgitation murmur	Suggests pulmonary hypertension
Growth	Below 10th centile for corrected age; Head sparing	Chronic illness effect

5. Diagnosis and Classification

NICHD 2001 Consensus Definition

The standard diagnostic criteria used worldwide. [1]

Diagnosis: Treatment with oxygen > 21% for at least 28 cumulative days

Severity Assessment Timepoint:

Infants born less than 32 weeks GA: Assess at 36 weeks PMA (or discharge if earlier)
Infants born ≥32 weeks GA: Assess at 56 days postnatal age (or discharge if earlier)

Severity Grading (at Assessment Timepoint)

Severity	Criteria at 36 Weeks PMA	Prognosis
Mild BPD	Breathing room air (no supplemental O2)	Generally good; rare long-term sequelae
Moderate BPD	Requiring less than 30% FiO2	Intermediate outcomes
Severe BPD	Requiring ≥30% FiO2 OR Positive pressure (CPAP, NIPPV, or mechanical ventilation)	Highest morbidity and mortality; often requires home O2; PH screening essential [1]

Jensen 2019 Revised Definition

A simplified, evidence-based redefinition with better outcome prediction. [16]

Grade	Respiratory Support at 36 Weeks PMA	Comments
Grade 1	No respiratory support, regardless of prior O2 history	Excellent prognosis
Grade 2	Nasal cannula ≤2 L/min	Good prognosis
Grade 3	Nasal cannula > 2 L/min OR CPAP/NIPPV	Moderate risk
Grade 3 (Severe)	Invasive mechanical ventilation	Highest risk; PH common

Exam Detail: Why the Jensen Definition Matters: The original NICHD definition was developed before high-flow nasal cannula (HFNC) became widespread. The Jensen definition better stratifies risk in the modern era by focusing on the type of respiratory support rather than just FiO2. [16]

Investigations

Mandatory Investigations

Investigation	Timing	Purpose	Expected Findings
Chest X-ray	Serial in NICU; PRN post-discharge	Assess lung parenchyma; Rule out complications	Hyperinflation, Hazy opacities, Cystic changes (severe)
Oxygen Saturation Monitoring	Continuous in NICU; Intermittent at home	Guide O2 therapy	Target SpO2 91-95%
Echocardiogram	At diagnosis of moderate/severe BPD; 6-8 weekly if abnormal	Screen for Pulmonary Hypertension	TR jet velocity; RV function; Septal position [9]
Blood Gas Analysis	When clinically indicated	Assess ventilation status	Chronic respiratory acidosis may be tolerated

Additional Investigations

Investigation	Indication	Clinical Utility
CT Chest (HRCT)	Severe/atypical BPD; Persistent symptoms	Mosaic attenuation; Air trapping; Structural abnormalities
Infant Pulmonary Function Testing	Research; Specialist centres	Quantify lung mechanics; Track response
Cardiac Catheterisation	Severe PH not responding to therapy	Definitive PH diagnosis; Vasoreactivity testing
Polysomnography	Before O2 weaning; Suspected OSA	Assess oxygenation during sleep
Swallow Assessment	Feeding difficulties	Rule out aspiration; Guide feeding route
Bronchoscopy	Atypical course; Suspected tracheomalacia	Assess airways; Obtain BAL

Chest X-ray Interpretation in BPD

Finding	Description	Severity Correlation
Hyperinflation	Flattened diaphragms; > 8 posterior ribs visible	Common in all grades
Hazy/Granular Opacities	Diffuse ground-glass appearance	Mild-Moderate BPD
Coarse Interstitial Markings	Increased bronchovascular markings	Moderate BPD
Cystic Changes	Focal lucencies; "Bubbly" appearance	Severe BPD; "Old BPD" phenotype
Cardiomegaly	CTR > 0.6	Suggests cor pulmonale/PH
Atelectasis	Segmental or lobar collapse	Common; May fluctuate

6. Prevention Strategies

Evidence-Based Prevention Hierarchy

Prevention is the cornerstone of BPD management. Multiple interventions with proven efficacy should be implemented systematically. [6,7,8,14,15]

Antenatal Interventions

Intervention	Evidence	Effect Size	Recommendation
Antenatal Corticosteroids (Betamethasone/Dexamethasone)	Cochrane review; Multiple RCTs [6]	RR 0.86 for BPD; NNT ~10	STRONGLY RECOMMENDED: Two doses of betamethasone 12mg IM 24h apart
Magnesium Sulphate (Neuroprotection)	Multiple RCTs	Reduces CP; No direct effect on BPD	Recommended for less than 32 weeks
Antenatal Optimisation	Observational	Variable	Transfer to tertiary centre; Delay delivery if possible
Chorioamnionitis Management	Indirect evidence	Reduces inflammation	Appropriate antibiotics; Consider delivery timing

Delivery Room Interventions

Intervention	Evidence	Recommendation
Delayed Cord Clamping (≥60 seconds)	Multiple RCTs	Improves haemodynamic stability; May reduce IVH; BPD effect unclear
Thermoregulation	Observational	Polyethylene wrap; Avoid hypothermia
Early CPAP (Rather Than Intubation)	COIN, SUPPORT trials [14]	Start CPAP in delivery room if breathing spontaneously
Surfactant (If Indicated)	Cochrane; Multiple RCTs	Early rescue surfactant if intubated for RDS

NICU Prevention Strategies

Respiratory Strategies

Intervention	Evidence Level	Mechanism	Key Trials
Non-Invasive Ventilation First (CPAP/NIPPV)	High [14]	Avoids VILI; Maintains FRC	COIN, SUPPORT, VON
Volume-Targeted Ventilation	Moderate	Reduces volutrauma; Consistent Vt delivery	Meta-analysis favours VTV
Early Surfactant + Rapid Extubation (INSURE)	High	Minimises ventilation duration	Multiple trials
Less-Invasive Surfactant Administration (LISA)	Emerging	Avoids intubation; Maintains CPAP	European trials positive
Permissive Hypercapnia	Moderate	Reduces ventilation intensity	pCO2 targets 50-65 mmHg
Oxygen Saturation Targeting 91-95%	High [8]	Balances O2 toxicity vs mortality	NeOProM meta-analysis

Exam Detail: LISA Technique: Less-Invasive Surfactant Administration involves delivering surfactant via a thin catheter while the infant remains on CPAP, avoiding the need for intubation. European trials show reduced BPD rates compared to INSURE (Intubate-Surfactant-Extubate). [14]

Pharmacological Prevention

Drug	Evidence	Dose	NNT	Notes
Caffeine Citrate	CAP Trial [7]	Load 20 mg/kg; Maint 5-10 mg/kg/day	10 for BPD/death	Start less than 72h of age; Continue until 34-36 weeks PMA
Vitamin A (Retinol)	Cochrane [15]	5000 IU IM 3x/week for 4 weeks	13	Requires IM injections; Variably adopted
Postnatal Steroids (Dexamethasone)	DART [17]	DART regimen (low-dose)	Variable	Reserve for ventilator-dependent infants > 7 days
Inhaled Corticosteroids (Budesonide)	NEUROSIS trial	Variable	Uncertain	May reduce BPD but not mortality; Not routine
Azithromycin	Emerging	10 mg/kg/day for 7 days	Under study	Anti-inflammatory; Promising trials

Caffeine Citrate: The Evidence

The Caffeine for Apnea of Prematurity (CAP) Trial is a landmark study demonstrating the remarkable benefits of caffeine. [7,11]

Outcome	Effect	Long-term Follow-up
BPD or Death at 36 weeks PMA	OR 0.63 (NNT 10)	Sustained benefit
Neurodevelopmental Disability at 18 months	OR 0.77	Better motor function
Cerebral Palsy	OR 0.58	Significant reduction
11-Year Follow-up	Improved motor function; Less functional impairment	Long-term benefits persist

Mechanism: Caffeine is an adenosine receptor antagonist with multiple beneficial effects:

Reduces apnoea → Earlier extubation
Anti-inflammatory effects → Reduced lung injury
Diuretic effect → Reduced pulmonary oedema
Improved respiratory muscle function

Nutritional Prevention

Strategy	Rationale	Target
Early Aggressive Nutrition	Prevents growth failure; Supports lung development	Start TPN day 1; Advance feeds rapidly
High Protein Intake	Reduces catabolism; Supports growth	3.5-4.5 g/kg/day
Optimised Caloric Intake	Energy for growth and repair	120-150 kcal/kg/day [13]
Human Milk (Preferably Mother's Own)	Immune factors; Anti-inflammatory	First choice; Donor milk if unavailable
Vitamin D Supplementation	Bone health; Immune function	400-1000 IU/day

Infection Prevention

Strategy	Mechanism	Evidence
Hand Hygiene	Reduces nosocomial infection	Fundamental
Central Line Bundles	Reduces CLABSI	Strong
Antibiotic Stewardship	Avoids dysbiosis; Reduces resistant organisms	Observational
Delayed Exposure to Pathogens	Reduces sepsis-related inflammation	Indirect

7. Management

Principles of BPD Management

Optimise Oxygenation: Adequate without toxicity (SpO2 91-95%)
Support Nutrition: Enable lung and somatic growth
Minimise Iatrogenic Harm: Avoid unnecessary interventions
Prevent and Treat Complications: PH surveillance; Infection prevention
Family-Centred Care: Education; Discharge preparation
Long-term Follow-up: Systematic developmental and respiratory surveillance

Respiratory Support

Oxygen Therapy

Aspect	Recommendation	Rationale
Target SpO2	91-95% (most centres)	Balances oxygen toxicity vs. mortality [8]
Monitoring	Continuous in NICU; Home oximetry	Detect desaturations; Guide weaning
Home Oxygen	For infants requiring O2 at discharge	Enables earlier discharge; Supports development
Weaning Approach	Gradual; Assess during sleep, feeds, activity	Most wean by 12-24 months

Ventilatory Support Hierarchy

Modality	Indication	Settings/Notes
Room Air	Mild BPD; SpO2 ≥91%	Goal for all infants
Low-Flow Nasal Cannula	Mild-Moderate BPD	≤2 L/min; Humidification helpful
High-Flow Nasal Cannula (HFNC)	Moderate BPD; Need for higher flow	2-8 L/min; Provides some CPAP effect
CPAP	Moderate-Severe BPD; Atelectasis	5-8 cmH2O; Maintains FRC
NIPPV	Failing CPAP; Ventilator weaning	Non-invasive PPV
Mechanical Ventilation	Severe BPD; Respiratory failure	Volume-targeted; Low Vt (4-6 mL/kg); Permissive hypercapnia
Tracheostomy + Home Ventilation	Severe BPD; Prolonged ventilator dependence	Rare; Specialist centres only

Pharmacological Management

Diuretics

Drug	Dose	Route	Indication	Monitoring
Furosemide	1-2 mg/kg/dose	PO/IV	Acute pulmonary oedema; Fluid overload	Electrolytes; Avoid long-term (ototoxicity, nephrocalcinosis)
Chlorothiazide	10-20 mg/kg/day divided BD	PO	Chronic BPD; Reduce pulmonary oedema	Electrolytes; Hypokalaemia
Spironolactone	1-3 mg/kg/day divided BD	PO	Potassium-sparing; Often combined with chlorothiazide	Hyperkalaemia risk

Clinical Pearl: Diuretic Combination Therapy: The combination of Chlorothiazide + Spironolactone ("Chlorthalidone-Spironolactone" or "Aldactazide") is commonly used in chronic BPD. This combination provides diuresis while minimising electrolyte disturbances. Monitor potassium and sodium regularly.

Postnatal Corticosteroids

Corticosteroids remain controversial due to significant neurodevelopmental concerns at higher doses. [17]

Regimen	Indication	Dose	Duration	Evidence
DART Protocol	Ventilator-dependent > 7 days; Failure to wean	Dexamethasone 0.89 mg/kg total course	10 days (tapered)	Reduces BPD with acceptable short-term safety [17]
Low-Dose Hydrocortisone	Some centres use as alternative	1-2 mg/kg/day	Variable	Less neurodevelopmental concern; Evidence evolving

DART Protocol (Dexamethasone): [17]

Day 1-3: 0.15 mg/kg/day
Day 4-6: 0.10 mg/kg/day
Day 7-8: 0.05 mg/kg/day
Day 9-10: 0.02 mg/kg/day

Exam Detail: Steroid Controversy: The DART trial showed that low-dose dexamethasone facilitates extubation and reduces BPD in ventilator-dependent infants. However, earlier trials using higher doses (particularly > 0.5 mg/kg/day) showed increased risk of cerebral palsy and developmental delay. Current guidance is to reserve steroids for infants at highest risk of death or severe BPD (i.e., still ventilated beyond 7-14 days). [17]

Bronchodilators

Drug	Use	Evidence	Notes
Salbutamol (Nebulised)	Acute wheezing; Before feeds in some	Limited	Response variable; May worsen tachycardia
Ipratropium Bromide	Combined with Salbutamol	Limited	May be useful in some
Inhaled Corticosteroids	Chronic wheeze; Post-discharge	Evidence for BPD weak	Often used empirically

Management of Pulmonary Hypertension in BPD

Pulmonary hypertension is the most serious complication of severe BPD, significantly increasing mortality. [9]

Treatment	Dose	Mechanism	Notes
Optimise Oxygenation	Maintain SpO2 > 92-95%	Reduces hypoxic vasoconstriction	First-line; Critical
Sildenafil	0.5-2 mg/kg TDS PO	Phosphodiesterase-5 inhibitor; Increases NO/cGMP	First-line pharmacotherapy
Inhaled Nitric Oxide (iNO)	5-20 ppm	Selective pulmonary vasodilator	Acute PH; Adjunct therapy
Bosentan	1-2 mg/kg BD PO	Endothelin receptor antagonist	Second-line; LFT monitoring

Nutritional Management

Principle	Target	Strategy
Caloric Intake	120-150 kcal/kg/day [13]	Fortified breast milk; High-calorie formula (24-27 kcal/oz)
Protein Intake	3.5-4.5 g/kg/day	Adequate protein for catch-up growth
Fluid Balance	Avoid overload; Concentrate feeds	130-150 mL/kg/day; May need restriction
Feeding Route	Oral preferred; NG if oral inadequate	NG bolus or continuous; Gastrostomy for prolonged need
Micronutrients	Iron, Vitamin D, Zinc	Routine supplementation; Monitor levels

RSV Prophylaxis (Palivizumab)

Palivizumab (Synagis) is a humanised monoclonal antibody against RSV F protein. [12]

Indication (UK/Australia Guidelines)	Dose	Schedule
BPD requiring treatment in last 6 months (O2, steroids, diuretics, bronchodilators)	15 mg/kg IM	Monthly during RSV season (typically Oct-Mar)
Born less than 29 weeks and less than 12 months at season start	15 mg/kg IM	Up to 5 doses
Haemodynamically significant CHD	15 mg/kg IM	As per guidelines
Severe Combined Immunodeficiency	15 mg/kg IM	Extended indications

Clinical Pearl: Palivizumab is NOT optional in BPD: Infants with BPD have 5-10x higher risk of RSV hospitalisation and significantly increased mortality from RSV bronchiolitis. The cost-effectiveness is well-established in this population. Ensure prescriptions are in place before discharge during RSV season. [12]

8. Complications and Long-Term Outcomes

Pulmonary Complications

Complication	Prevalence	Mechanism	Management
Pulmonary Hypertension	10-25% of severe BPD [9]	Vascular remodelling; Hypoxic vasoconstriction	Sildenafil; iNO; Avoid hypoxia
Recurrent Respiratory Infections	Very common	Impaired mucosal immunity; Structural abnormalities	Low admission threshold; RSV prophylaxis [12]
Reactive Airways Disease	30-40%	Airway hyperreactivity; Possible true asthma	Bronchodilators; ICS trial
Tracheobronchomalacia	10-15% of severe	ETT-related; Chronic inflammation	Bronchoscopy diagnosis; CPAP; Aortopexy rarely
Subglottic Stenosis	2-5%	Prolonged intubation	ENT assessment; Balloon dilation; Surgical repair
Air Leak Syndromes	During acute phase	Ventilator-induced; Cystic changes	Chest drain; Optimise ventilation

Cardiovascular Complications

Complication	Prevalence	Clinical Features	Management
Cor Pulmonale	Secondary to PH	RV failure; Hepatomegaly; Oedema	Treat underlying PH; Diuretics
Systemic Hypertension	Increased incidence	Often multifactorial	Monitor; Antihypertensives if needed
Left Ventricular Dysfunction	Less common	May reflect chronic hypoxia	Echo surveillance

Growth and Nutritional Complications

Complication	Prevalence	Contributing Factors	Management
Failure to Thrive	30-50%	High metabolic demand; Poor intake; GORD	Calorie fortification; Feeding support; NG/Gastrostomy
Oral Aversion	Common	Prolonged intubation; NICU experience	Speech therapy; Sensory integration
Gastro-Oesophageal Reflux	Very common	Diaphragmatic dysfunction; Medications	Thickened feeds; Positioning; PPI/H2RA
Metabolic Bone Disease	Background prematurity complication	Calcium/Phosphorus deficiency	Supplementation; Monitor ALP

Neurodevelopmental Outcomes

Outcome	Prevalence in BPD	Comparison to Non-BPD Preterm	Risk Factors
Cerebral Palsy	10-15% (severe BPD)	2-3x higher	Severe BPD; IVH; PVL
Cognitive Delay	25-40%	1.5-2x higher	Prolonged ventilation; Steroids
Motor Impairment	20-30%	Higher	Related to CP; Muscle weakness
Behavioural Problems	Common	Higher	NICU experience; Chronic illness
Educational Difficulties	Common	Higher	Multifactorial

Long-Term Respiratory Outcomes (Into Adulthood)

Studies following BPD survivors into adolescence and adulthood reveal persistent abnormalities. [10]

Finding	Prevalence	Clinical Implications
Abnormal Spirometry	50-70%	FEV1 reduced; FEV1/FVC reduced (obstructive pattern)
Reduced Exercise Capacity	40-60%	VO2 max decreased; Exercise-induced symptoms
Bronchial Hyperreactivity	30-40%	Positive methacholine challenge
Persistent Symptoms	30-50%	Wheeze, cough, dyspnoea on exertion
CT Abnormalities	50-80%	Mosaic attenuation; Air trapping; Emphysema
Accelerated Lung Function Decline	Emerging evidence	COPD-like trajectory; Never achieve peak lung function
Reduced Peak Lung Function	Common	May never reach predicted maximum; Early decline

Evidence Debate: BPD and Adult COPD: There is increasing concern that BPD survivors may represent a novel "early-onset COPD" phenotype. Many never achieve predicted peak lung function in their 20s and may experience accelerated decline thereafter. This has implications for smoking prevention (absolute contraindication in BPD survivors), environmental exposures, and long-term respiratory surveillance. [10]

Prognostic Factors

Factor	Impact	Strength of Association
BPD Severity	Severe > Moderate > Mild	Strong
Pulmonary Hypertension	Significantly increases mortality (up to 50% 2-year mortality if severe) [9]	Very Strong
Gestational Age	Lower GA = Worse outcomes	Strong
Postnatal Growth	Poor growth = Worse outcomes	Strong
Socioeconomic Status	Lower SES = Higher rehospitalisation	Moderate
Passive Smoke Exposure	Worsens respiratory outcomes	Strong

9. Follow-Up and Surveillance

Structured Follow-Up Framework

Clinic	Frequency	Focus Areas
Neonatal Follow-Up	Monthly initially → 3-6 monthly	Growth; Respiratory status; Feeding; General health
Respiratory Paediatrics	3-6 monthly until stable	O2 weaning; Airways management; PFTs
Paediatric Cardiology	As indicated by Echo findings	PH surveillance; Interval Echo
Developmental Paediatrics	6-12 monthly	Neurodevelopmental assessment; Early intervention
Ophthalmology	Per ROP screening schedule	ROP follow-up (if applicable)
Dietitian	As needed	Nutritional optimisation
Speech Therapy	If feeding difficulties	Oral motor skills; Swallow assessment

Home Oxygen Weaning Protocol

Assessment	Criteria	Action
Readiness Assessment	Stable respiratory status; Adequate growth; No acute illness	Consider weaning trial
Oximetry Study	SpO2 ≥91% in room air during sleep, feeds, activity	If passed, trial daytime weaning
Daytime Wean	Remove O2 during daytime hours; Monitor	If stable, proceed to overnight study
Overnight Study (Polysomnography)	SpO2 ≥91% throughout sleep; No significant desaturations	Discontinue O2 if passed
Typical Timeline	Most wean by 12-24 months corrected age	Some severe BPD: 2-3 years

Discharge Criteria for Infants on Home Oxygen

Domain	Requirement
Clinical Stability	No acute illness; Stable for ≥1 week
Oxygen Requirement	Stable FiO2 for ≥72 hours
Growth	Consistent weight gain on current feeds
Parental Competence	Trained in O2 equipment, feeding, medication administration, CPR
Equipment	Home oxygen supply, Pulse oximeter, Suction (if needed)
Emergency Plan	Written action plan; Contact numbers; Transport arranged
Follow-Up	Appointments booked; Palivizumab arranged if in season [12]
Community Support	GP notified; Health visitor; Community nursing if required

10. Evidence Base and Guidelines

Key Guidelines

Guideline	Organisation	Key Recommendations
AAP Clinical Report on BPD	American Academy of Pediatrics	Prevention strategies; Definition; Management principles
BAPM Framework for Neonatal Care	British Association of Perinatal Medicine	O2 saturation targets; Service standards
European Consensus Guidelines	European Society of Paediatric Research	Comprehensive evidence synthesis; Ventilation strategies
NICE: Specialist Neonatal Care	National Institute for Health and Care Excellence	Quality standards; Prevention
Australian Guidelines	PSANZ/RACP	Palivizumab; Follow-up recommendations

Landmark Clinical Trials

Trial	Year	Key Finding	Impact
CAP Trial [7]	2006	Caffeine reduces BPD/death (OR 0.63; NNT 10)	Caffeine now standard of care for less than 30 weeks
CAP 18-Month Follow-up [11]	2007	Improved neurodevelopmental outcomes with caffeine	Reinforced universal caffeine use
SUPPORT Trial [8]	2010	Lower O2 targets (85-89%) reduce BPD but increase mortality	Led to consensus targeting 91-95%
BOOST II (UK, Australia, NZ)	2013	Lower O2 targets increase mortality	Confirmed NeOProM findings
NeOProM Meta-analysis [8]	2018	Lower O2: Less BPD, Less ROP, ~1% higher mortality	Informed current targets
COIN Trial [14]	2008	Early CPAP vs Intubation: CPAP non-inferior; Less BPD	Supported early CPAP approach
DART Trial [17]	2006	Low-dose dexamethasone facilitates extubation	Provides regimen for ventilator-dependent infants
Tyson BPD Predictor Study	2008	BPD risk calculator for ELBW infants	Clinical risk stratification
NEUROSIS Trial	2014	Inhaled budesonide reduces BPD; No mortality benefit	Variable adoption; Not routine
Jensen Revised Definition [16]	2019	Respiratory support-based BPD grading	Better outcome prediction

11. Examination Scenarios and Model Answers

Scenario 1: Definition and Classification

Stem: A 26-week gestation infant has required supplemental oxygen since birth. At 36 weeks PMA, they require 28% FiO2 via nasal cannula. What is the diagnosis and severity?

Model Answer:

Diagnosis: Bronchopulmonary Dysplasia (BPD)
Rationale: Required oxygen for ≥28 days (criterion met) [1]
Severity: Moderate BPD (Requires less than 30% FiO2 at 36 weeks PMA)
Using Jensen Definition: Grade 2 if on ≤2 L/min nasal cannula [16]
Key Management Points: Continue SpO2 targeting 91-95%; Echocardiogram to screen for pulmonary hypertension; Nutritional optimisation; Palivizumab if RSV season; Discharge planning with home oxygen

Scenario 2: Prevention Strategies

Stem: What evidence-based interventions prevent BPD in extremely preterm infants?

Model Answer (in order of evidence strength):

Antenatal Corticosteroids: Cochrane evidence; NNT ~10; Accelerate lung maturation [6]
Caffeine Citrate: CAP Trial; NNT 10 for BPD/death; Start within 72 hours [7]
Non-invasive Respiratory Support (CPAP): COIN/SUPPORT trials; Avoid intubation if possible [14]
Surfactant Therapy: Reduces RDS severity; Enables gentler ventilation
Oxygen Saturation Targeting 91-95%: NeOProM meta-analysis; Balances lung protection and mortality [8]
Volume-Targeted Ventilation: If ventilation needed; Reduces volutrauma
Vitamin A Supplementation: Cochrane review; NNT 13; Supports epithelial repair [15]
Nutritional Optimisation: 120-150 kcal/kg/day; Supports lung growth [13]
Infection Prevention: Reduces inflammatory burden

Scenario 3: Caffeine Mechanism

Stem: A medical student asks why caffeine is important in BPD prevention. Explain the evidence and mechanisms.

Model Answer: The CAP (Caffeine for Apnea of Prematurity) Trial is the landmark RCT demonstrating caffeine's benefits. [7,11]

Evidence:

Reduced BPD or death at 36 weeks PMA (OR 0.63; NNT 10)
Improved neurodevelopmental outcomes at 18 months
Benefits persist to 11 years (improved motor function)

Mechanisms:

Adenosine Receptor Antagonism: Reduces apnoea; Improves respiratory drive
Earlier Extubation: Less time on mechanical ventilation; Less VILI
Anti-inflammatory Effects: Reduces pulmonary inflammation
Diuretic Effect: Reduces pulmonary oedema
Improved Respiratory Muscle Function: Enhances diaphragmatic contractility

Practice Point: Start caffeine within 24-72 hours of birth in all infants less than 30 weeks gestation.

Scenario 4: Parent Counselling

Stem: A mother asks why her baby with BPD is receiving monthly injections. Explain Palivizumab.

Model Answer: "Your baby has BPD, which means their lungs are still developing and are more vulnerable than those of a full-term baby. The monthly injection is called Palivizumab (Synagis).

What it does: It contains antibodies that protect against RSV (Respiratory Syncytial Virus). RSV causes bronchiolitis—a common winter infection. For most babies, it's just a cold, but for babies with BPD, it can be very serious and require intensive care. [12]

Why it's important: Babies with BPD are 5-10 times more likely to need hospital admission with RSV. Palivizumab significantly reduces this risk.

Schedule: One injection every month during RSV season (usually October to March).

Other precautions: Avoid contact with people who have colds; Good hand hygiene; Avoid crowded indoor spaces during winter."

Scenario 5: Old vs New BPD

Stem: Describe the differences between "Old BPD" and "New BPD."

Model Answer:

Feature	Old BPD (Northway 1967) [4]	New BPD (Post-Surfactant Era) [5]
Population	Larger preterm (30-34 weeks)	Extremely preterm (less than 28 weeks)
Primary Injury	Severe ventilator trauma + high FiO2	Developmental arrest + subtle injury
Pathology	Fibrosis; Airway smooth muscle hypertrophy; Epithelial injury	Simplified alveoli (fewer, larger); Dysmorphic vasculature; Minimal fibrosis
CXR Appearance	Cystic changes; Fibrotic stranding	Hazy opacities; Hyperinflation
Cause of Shift	Introduction of surfactant; Gentler ventilation; Improved survival of ELBW

Clinical Significance: "New BPD" is primarily a developmental disorder—the extremely preterm lung fails to complete normal alveolarisation. This has implications for long-term outcomes (persistent simplified lung architecture) and treatment (focus on supporting development rather than treating fibrosis).

Scenario 6: Pulmonary Hypertension Management

Stem: A 3-month-old with severe BPD is found to have pulmonary hypertension on echocardiography (TR jet 4.2 m/s, flattened septum). What is your management?

Model Answer: Assessment (TR jet 4.2 m/s suggests estimated RVSP ~70 mmHg + RAP—significant PH): [9]

Immediate:
- Ensure optimal oxygenation (target SpO2 ≥92-95%)—hypoxia drives pulmonary vasoconstriction
- Review and optimise current respiratory support
Pharmacological Treatment:
- First-line: Sildenafil 0.5-2 mg/kg TDS orally
- Consider inhaled nitric oxide for acute deterioration
Ongoing Management:
- Serial echocardiography (6-8 weekly initially)
- Cardiology involvement essential
- Consider cardiac catheterisation if:
  - Failure to respond to treatment
  - Need for vasoreactivity testing
  - Severe/progressive PH
Adjunctive Measures:
- Avoid hypoxia (may need higher O2 targets)
- Nutritional optimisation
- Diuretics if fluid overloaded
- Treat underlying infections aggressively
Prognosis Discussion:
- PH significantly worsens prognosis (up to 50% 2-year mortality if severe)
- Honest discussion with family required

12. Triage and Referral Pathways

Clinical Scenario	Urgency	Action
Preterm infant with evolving BPD (stable, in NICU)	Routine	Neonatal team management; Optimise prevention strategies
Severe BPD, ventilator-dependent beyond 28 days	NICU care	Consider DART protocol steroids; Tertiary NICU if not already
Home O2 infant with acute respiratory illness	URGENT/EMERGENCY	Hospital assessment; Low threshold for admission
Desaturation episodes at home	URGENT	Same-day paediatric review; Consider infection/PH
Suspected pulmonary hypertension (loud P2, RV heave)	URGENT	Echocardiogram; Cardiology referral
Feeding difficulties with weight loss	Urgent	Dietitian; Speech therapy; Consider NG/Gastrostomy
Developmental concerns	Routine/Urgent	Developmental paediatrics; Early intervention services
Subglottic stridor after extubation	Urgent	ENT assessment; Laryngoscopy
Progressive respiratory failure despite treatment	EMERGENCY	Consider escalation; Tertiary centre transfer

13. Quality Markers and Audit Standards

Quality Standard	Target	Rationale
Antenatal corticosteroids given to eligible mothers less than 34 weeks	> 90%	Reduces BPD (NNT ~10) [6]
Caffeine started within 72 hours in infants less than 30 weeks	> 95%	CAP Trial evidence [7]
SpO2 targets 91-95% documented and followed	100%	Avoid O2 toxicity [8]
Non-invasive ventilation attempted before intubation (if appropriate)	> 80%	COIN/SUPPORT evidence [14]
Echocardiography for severe BPD (PH screening)	100%	Detect PH early [9]
Palivizumab offered to all eligible infants	100%	Prevent RSV morbidity [12]
Discharge infants on home O2 have documented action plan	100%	Safety
Neonatal follow-up arranged before discharge	100%	Continuity of care
Growth velocity > 15 g/kg/day in NICU	> 80%	Nutritional adequacy [13]
Parents trained in CPR before home oxygen discharge	100%	Safety

14. Patient and Family Information

What is BPD?

Bronchopulmonary Dysplasia (BPD), also called Chronic Lung Disease of Prematurity, is a lung condition affecting babies born very early. When babies are born before their lungs are fully developed (usually before 28 weeks), the treatments needed to help them survive—like oxygen and breathing machines—can cause inflammation and slow down lung growth.

Why Did My Baby Get BPD?

Your baby was born very early, when their lungs were still developing. The lungs of a baby born at 26 weeks are very different from those of a full-term baby—they don't yet have the millions of tiny air sacs (alveoli) needed for normal breathing. The oxygen and breathing support your baby needed to survive can cause some injury to these developing lungs. This isn't anyone's fault—it's a consequence of the medical technology that allowed your baby to survive.

What Treatment Will My Baby Need?

Treatment	Purpose
Oxygen	Many babies need extra oxygen at home until their lungs grow stronger—usually for months to 1-2 years
Medications	Diuretics (water tablets) help clear fluid from the lungs; Sometimes inhaled medications if wheezing
RSV Protection	Monthly injections during winter protect against a dangerous virus [12]
Good Nutrition	Extra calories help your baby grow, and growing helps lungs heal
Regular Check-ups	Monitoring growth, lung function, and development

Will My Baby Get Better?

Most babies with BPD improve as they grow. The lungs continue developing for the first 2-3 years of life. Many children with BPD go on to lead active, healthy lives. Some children may have ongoing breathing problems like wheezing or reduced exercise tolerance, but these can usually be managed.

Key Counselling Points for Parents

Topic	Key Message
Lung Growth	"Your baby's lungs will continue to grow and heal over the first 2-3 years"
RSV Danger	"Please keep your baby away from people with colds. The monthly injection protects against the most dangerous virus" [12]
Smoke-Free	"Second-hand smoke makes lung problems much worse. No one should smoke around your baby"
Nutrition	"Good feeding and weight gain help the lungs grow"
Follow-Up	"Regular check-ups help us wean oxygen and catch any problems early"
Hand Hygiene	"Wash hands before touching your baby; Ask visitors to do the same"
Crowds	"Avoid crowded indoor places, especially in winter"

Frequently Asked Questions

Question	Answer
"Why does my baby need oxygen at home?"	Your baby's lungs are still developing. The oxygen supports them while they grow.
"How long will my baby be on oxygen?"	It varies—usually months to 1-2 years. We'll wean as the lungs mature.
"Is RSV really that dangerous?"	Yes. Babies with BPD can get very sick from RSV. The monthly injection protects against it. [12]
"Will my baby have asthma?"	Some children with BPD have wheeze or asthma-like symptoms. Not all do.
"Can I take my baby outside?"	Yes, fresh air is fine. Avoid crowded indoor spaces and sick people, especially in winter.
"When can we stop the oxygen?"	When your baby can maintain their oxygen levels during sleep, feeds, and activity without it.

15. Historical Perspective

William Northway and the First Description (1967)

In 1967, William Northway and colleagues at Stanford University published a landmark paper describing a new lung disease in preterm infants who survived with oxygen and mechanical ventilation. [4]

Original Case Series:

32 infants with Respiratory Distress Syndrome (RDS) who survived with O2 and mechanical ventilation
Described severe lung injury at autopsy and on chest X-rays
Four stages of pathological progression:
- "Stage I: Acute RDS"
- "Stage II: Regeneration with necrosis"
- "Stage III: Transition to chronic disease"
- "Stage IV: Chronic pulmonary fibrosis"

Terminology: Northway named the condition "Bronchopulmonary Dysplasia"—dysplasia meaning abnormal growth/development.

Evolution of the Disease

Era	Key Developments	Impact on BPD
1960s-1970s	First mechanical ventilators; High pressures/volumes	"Old BPD" with severe fibrosis
1980s	Recognition of oxygen toxicity; Lower O2 targets introduced	Reduced severe fibrotic disease
1990s	Surfactant therapy introduced; CPAP more widely used	Survival of smaller infants; "New BPD" emerges
2000s	CAP Trial (caffeine); NeOProM (oxygen targets); NICHD definition [1,7]	Evidence-based prevention
2010s-Present	LISA; Revised definitions; Long-term follow-up studies [10,16]	Focus on developmental support; Understanding of adult outcomes

16. References

Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001;163(7):1723-1729. doi:10.1164/ajrccm.163.7.2011060 PMID: 11401896
Stoll BJ, Hansen NI, Bell EF, et al. Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993-2012. JAMA. 2015;314(10):1039-1051. doi:10.1001/jama.2015.10244 PMID: 26348753
Bancalari E, Claure N, Sosenko IRS. Bronchopulmonary dysplasia: changes in pathogenesis, epidemiology and definition. Semin Neonatol. 2003;8(1):63-71. doi:10.1016/S1084-2756(02)00192-6 PMID: 12667831
Northway WH Jr, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med. 1967;276(7):357-368. doi:10.1056/NEJM196702162760701 PMID: 5334613
Coalson JJ. Pathology of new bronchopulmonary dysplasia. Semin Neonatol. 2003;8(1):73-81. doi:10.1016/S1084-2756(02)00193-8 PMID: 12667832
Roberts D, Brown J, Medley N, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2017;3(3):CD004454. doi:10.1002/14651858.CD004454.pub3 PMID: 28321847
Schmidt B, Roberts RS, Davis P, et al. (CAP Trial Group). Caffeine therapy for apnea of prematurity. N Engl J Med. 2006;354(20):2112-2121. doi:10.1056/NEJMoa054065 PMID: 16707748
Askie LM, Darlow BA, Finer N, et al. (NeOProM Collaboration). Association between oxygen saturation targeting and death or disability in extremely preterm infants. JAMA. 2018;319(21):2190-2201. doi:10.1001/jama.2018.5725 PMID: 29872859
Krishnan U, Feinstein JA, Adatia I, et al. Evaluation and management of pulmonary hypertension in children with bronchopulmonary dysplasia. J Pediatr. 2017;188:24-34.e1. doi:10.1016/j.jpeds.2017.05.029 PMID: 28645441
Doyle LW, Adams AM, Robertson C, et al. Increasing airway obstruction from 8 to 18 years in extremely preterm/low-birthweight survivors born in the surfactant era. Thorax. 2017;72(8):712-719. doi:10.1136/thoraxjnl-2016-208524 PMID: 27909161
Schmidt B, Roberts RS, Davis P, et al. Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med. 2007;357(19):1893-1902. doi:10.1056/NEJMoa073679 PMID: 17989382
Simões EAF, Bont L, Manzoni P, et al. Past, present and future approaches to the prevention and treatment of respiratory syncytial virus infection in children. Infect Dis Ther. 2018;7(1):87-120. doi:10.1007/s40121-018-0188-z PMID: 29470837
Ehrenkranz RA, Dusick AM, Vohr BR, et al. Growth in the neonatal intensive care unit influences neurodevelopmental and growth outcomes of extremely low birth weight infants. Pediatrics. 2006;117(4):1253-1261. doi:10.1542/peds.2005-1368 PMID: 16585322
Morley CJ, Davis PG, Doyle LW, et al. (COIN Trial Investigators). Nasal CPAP or intubation at birth for very preterm infants. N Engl J Med. 2008;358(7):700-708. doi:10.1056/NEJMoa072788 PMID: 18272893
Darlow BA, Graham PJ, Rojas-Reyes MX. Vitamin A supplementation to prevent mortality and short- and long-term morbidity in very low birth weight infants. Cochrane Database Syst Rev. 2016;(8):CD000501. doi:10.1002/14651858.CD000501.pub4 PMID: 27552058
Jensen EA, Dysart K, Gantz MG, et al. The diagnosis of bronchopulmonary dysplasia in very preterm infants: an evidence-based approach. Am J Respir Crit Care Med. 2019;200(6):751-759. doi:10.1164/rccm.201812-2348OC PMID: 30995069
Doyle LW, Davis PG, Morley CJ, et al. (DART Study Investigators). Low-dose dexamethasone facilitates extubation among chronically ventilator-dependent infants. Pediatrics. 2006;117(1):75-83. doi:10.1542/peds.2004-2843 PMID: 16396863
Ehrenkranz RA, Walsh MC, Vohr BR, et al. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics. 2005;116(6):1353-1360. doi:10.1542/peds.2005-0249 PMID: 16322158
Abman SH, Collaco JM, Shepherd EG, et al. Interdisciplinary care of children with severe bronchopulmonary dysplasia. J Pediatr. 2017;181:12-28.e1. doi:10.1016/j.jpeds.2016.10.082 PMID: 27908648
Thébaud B, Goss KN, Laughon M, et al. Bronchopulmonary dysplasia. Nat Rev Dis Primers. 2019;5(1):78. doi:10.1038/s41572-019-0127-7 PMID: 31727978

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Always consult your medical team for individual patient care decisions.

Clinical board

Urgent signals

Exam focus

Linked comparisons

Editorial and exam context

Bronchopulmonary Dysplasia (BPD)

1. Topic Overview (Clinical Overview)

Summary

Key Facts

Clinical Pearls

Why This Matters Clinically

2. Epidemiology

Global Incidence and Prevalence

Temporal Trends

Geographic Variation

Risk Factor Analysis

Major Risk Factors

Protective Factors

Survival and Mortality Context

3. Pathophysiology

Fetal Lung Development: The Foundation

"Old BPD" vs "New BPD": A Paradigm Shift

Molecular Pathophysiology

Key Signalling Pathways Disrupted in BPD

Cellular Mechanisms

The Four Pillars of BPD Pathogenesis

1. Mechanical Ventilation Injury

2. Oxygen Toxicity and Oxidative Stress

3. Inflammation (Prenatal and Postnatal)

4. Nutritional Deficiency and Growth Failure

Pulmonary Vascular Pathology in BPD

4. Clinical Presentation

Acute Phase (NICU - First Weeks)

Transition Phase (Approaching Term Equivalent)

Chronic Phase (Post-Discharge - First Years)

Physical Examination Findings

5. Diagnosis and Classification

NICHD 2001 Consensus Definition

Severity Grading (at Assessment Timepoint)

Jensen 2019 Revised Definition

Investigations

Mandatory Investigations

Additional Investigations

Chest X-ray Interpretation in BPD

6. Prevention Strategies

Evidence-Based Prevention Hierarchy

Antenatal Interventions

Delivery Room Interventions

NICU Prevention Strategies

Respiratory Strategies

Pharmacological Prevention

Caffeine Citrate: The Evidence

Nutritional Prevention

Infection Prevention

7. Management

Principles of BPD Management

Respiratory Support

Oxygen Therapy

Ventilatory Support Hierarchy

Pharmacological Management

Diuretics

Postnatal Corticosteroids

Bronchodilators

Management of Pulmonary Hypertension in BPD

Nutritional Management

RSV Prophylaxis (Palivizumab)

8. Complications and Long-Term Outcomes

Pulmonary Complications

Cardiovascular Complications

Growth and Nutritional Complications

Neurodevelopmental Outcomes

Long-Term Respiratory Outcomes (Into Adulthood)

Prognostic Factors

9. Follow-Up and Surveillance

Structured Follow-Up Framework

Home Oxygen Weaning Protocol

Discharge Criteria for Infants on Home Oxygen

10. Evidence Base and Guidelines

Key Guidelines

Landmark Clinical Trials